Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estrogen Priming in Operable Breast Cancer
NCT00193726Phase 3Terminated
- Start
- Jul 2005
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of conjugated estrogens in breast cancer (2 arms). Primary endpoint: Disease Free Survival at 60 months. Started Jul 2005; status: terminated.
02
Drugs
conjugated estrogens
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00193726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193726.